Elicio Therapeutics (ELTX) Share-based Compensation (2020 - 2026)

Elicio Therapeutics (ELTX) has reported Share-based Compensation for 7 consecutive years, with $935000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation rose 31.69% year-over-year to $935000.0; the trailing twelve-month figure through Jun 2026 stood at $3.3 million (up 63.24% YoY), and the FY2025 full-year result was $2.7 million, up 85.74% from the prior year.
• Share-based Compensation rose to $935000.0 in Q2 2026 per ELTX's latest filing, from $868000.0 in the prior quarter.
• Across five years, Share-based Compensation topped out at $935000.0 in Q2 2026 and bottomed at $31000.0 in Q1 2022.
• Historically, Share-based Compensation has averaged $428333.3 across 5 years, with a median of $338000.0 in 2023.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation plunged 99.39% in 2022, then jumped 622.58% in 2023.
• Over 5 years, Share-based Compensation stood at $199000.0 in 2022, then soared by 69.35% to $337000.0 in 2023, then jumped by 37.69% to $464000.0 in 2024, then soared by 66.38% to $772000.0 in 2025, then climbed by 21.11% to $935000.0 in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $935000.0, $868000.0, and $772000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.